In general, TAMs can directly promote T-cell apoptosis by expressing Fas L and TRAIL to further inhibit the activity of T cells, thereby enhancing the immune escape ability of tumor cells and leading to resistance to PD-1/PD-L1 therapy. The gene discussed is PDCD1; the disease is neoplasm.